论文部分内容阅读
目的探讨依达拉奉治疗急性重型脑损伤的临床疗效。方法对本院2010年3月-2012年3月外科ICU收治高血压脑出血引起的急性重型脑损伤患者90例临床资料进行回顾性的分析,依据是否应用依达拉奉将90例急性重型脑损伤患者分为对照组30例和依达拉奉组60例。结果依达拉奉组治疗急性重型脑损伤的临床疗效明显优于对照组,P<0.05,差异有统计学意义。结论采用静脉注射依达拉奉的方法对患有高血压脑出血后急性重型脑损伤患者进行治疗的临床疗效理想,值得临床借鉴应用。
Objective To investigate the clinical efficacy of edaravone in the treatment of acute severe brain injury. Methods The clinical data of 90 patients with acute severe brain injury caused by hypertensive intracerebral hemorrhage in our hospital from March 2010 to March 2012 were retrospectively analyzed. According to whether edaravone 90 cases of acute severe brain injury Injury patients were divided into control group 30 cases and edaravone group 60 cases. Results Edaravone treatment of acute severe brain injury clinical efficacy was significantly better than the control group, P <0.05, the difference was statistically significant. Conclusion The clinical efficacy of intravenous edaravone in patients with acute severe brain injury after hypertensive intracerebral hemorrhage is worthy of clinical reference.